Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced a distribution and marketing agreement with LEO Pharma, granting the latter exclusive rights to market and sell toripalimab in the EU, EEA, Switzerland, and the UK. This partnership includes an upfront payment of EUR15 million and a revenue-sharing model, enhancing Junshi Biosciences’ presence in the European market and potentially expanding their global reach in oncology therapeutics.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative drugs. The company specializes in immuno-oncology drugs, particularly anti-PD-1 monoclonal antibodies, such as toripalimab, which has been approved for multiple indications across several countries.
YTD Price Performance: -6.39%
Average Trading Volume: 1,251,277
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$23.44B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.
